Table 3.
Actionable genomic alterations relevant for the treatment decision according to the AGO recommendation of 2019 version 1.0 [1]
| Breast cancer: actionable genomic alterations | ||||
|---|---|---|---|---|
| factorsa | outcome | LoE2009 | CTS | AGO |
| Evidence from studies with breast cancer patients | ||||
| sPIK3CA mutation | efficacy of anti-HER2 therapies | I | B | +/–b |
| sPIK3CA mutation | efficacy of endocrine therapy | I | B | +/–b |
| sESRl mutation | efficacy of endocrine therapy | II | B | +/–b |
| sHER2 mutation | efficacy of anti–HER2 therapies | II | B | +/–b |
| sBRCAl/2 oder gBRCAl/2 | efficacy of platinum chemotherapy | II | B | +/–b |
| sBRCAl/2 oder gBRCAl/2 | efficacy of chemotherapy | II | B | +/–b |
| oder gBRCAl/2 | efficacy of PARP Inhibitors | I | A | +b |
| Evidence from studies with other cancer patients | ||||
| Companion diagnostics for therapies of other tumors entities | efficacy of diverse therapies | IV | D | +/–b |
| (e.g., BRAF and FGFR1) Large panel gene analysis | efficacy of diverse therapies, prognosis | III | C | +/–b |
| (e.g., FoundationOne, GPS cancer, NeoSelect, molecular health guide, local “hand-selected” panels) | ||||
a
Assessment method of somatic mutations is not taken into consideration for LoE.
b
Participation in clinical trials or structured registries recommended (s = somatic; g = germline).
CTS, clinical treatment score; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit- α; ESR1, estrogen receptor gene 1; BRAF, serin/threonin-kinase B-Raf (rapidly accelerated fibrosarcoma); FGFR1, fibroblast growth factor-1; gBRCA 1/2, germline BRCA1/2 gene.